September 3, 2019 10:22 AM EDT
Financing
R&D
Cell/Gene Tx

Syn­cona dives deep in­to dry AMD R&D, up­ping Gy­ro­scope bet to $100M

Jason Mast

Editor

The ex­plo­sion of gene ther­a­pies in the clin­ic promis­es to trans­form the treat­ment of eye dis­eases. And Syn­cona thinks one of their port­fo­lio com­pa­nies may …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times